ClinicalTrials.gg
CompletedNCT07942961Updated Nov 17, 2026

Evaluation of a Values-Clarification Tool for Older Adults With Cancer

An interventional study of Values-clarification decision support tool and No intervention in Cancer and Malignancy, sponsored by UNC Lineberger Comprehensive Cancer Center. Completed at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by UNC Lineberger Comprehensive Cancer Center · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Registered 2 years 2 months after the study started (first participant enrolled Sep 2024, registered Nov 2026).
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

This randomized pilot study will evaluate whether a decision support tool can improve values clarification and shared decision-making (SDM) among older adults with advanced-stage cancer. The tool, developed previously, helps patients identify their personal values and provides tailored feedback and relevant questions to support treatment discussions. Participants will be randomly assigned to intervention or control groups and take part in simulated patient-clinician consultations. The study aims to assess and compare the quality of values clarification and SDM processes between the two groups.

02

Conditions studied

  • Cancer
  • Malignancy

Browse trials for

Keywords

  • shared decision making
  • decision support tool
  • ELDERLY
03

In context

Neoplasms

10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's enrollment of 46 is below the median of 60 across 7,712 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

UNC Lineberger Comprehensive Cancer Center is the lead sponsor of 430 studies on the registry; 95 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained to participate in the study and HIPAA authorization for release of personal health information.
  • Subjects is willing and able to comply with study procedures based on the judgement of the investigator.
  • Age is 60 years or above at the time of consent (patients).
  • Current or previous cancer diagnosis at advanced stage, not limited by site.

Exclusion criteria

Exclusion Criteria:

  • Dementia, altered mental status, or psychiatric condition that would prohibit the understanding or rendering of or participation in the intervention.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Intervention group

    Participants assigned to the intervention group will receive the values-clarification decision support tool, which guides them in identifying their personal values, preferences, and priorities regarding cancer treatment. The tool also provides tailored feedback and relevant questions to help participants communicate their preferences and support discussions with the clinician during simulated consultations.

    Behavioral: Values-clarification decision support tool

  • Active comparator
    Control group

    Participants receive contextualized cancer-related educational information from the American Cancer Society and do not receive the values-clarification decision support tool.

    Other: No intervention

Interventions

  • BehavioralValues-clarification decision support tool

    Participants assigned to the intervention group will receive a decision support tool designed for older adults with advanced-stage cancer. The tool helps participants identify and clarify their personal values, preferences, and priorities regarding cancer treatment. It also provides tailored feedback and relevant questions from question prompt lists (QPLs) to support communication and shared decision-making during simulated clinical consultations.

  • OtherNo intervention

    Participants will receive contextualized cancer-related educational information from the American Cancer Society.

06

What researchers measure

Primary outcomes

  1. Quality of Values Clarification

    The primary endpoint is the quality of values-clarification processes during simulated clinical consultations, measured using a standardized checklist developed by the study team. Checklist scores will range from 0 to 100, with higher scores indicating better quality of values clarification. Scores will be compared between participants who receive the values-clarification decision support tool (intervention group) and those who receive American Cancer Society educational information (control group), overall and stratified by consultation type (values-based and non-values-based). Higher scores indicate better quality.

    Time frame: Baseline, Up to 1 hour

Secondary outcomes

  1. Participants' Perceptions of the Decision Support Tool and Shared Decision-Making

    Participants' perceptions will be assessed through semi-structured interviews and questionnaires to evaluate: (1) their experiences and perceptions of receiving tailored feedback and content-matched questions based on their stated values; (2) their perceptions of the values-clarification process; and (3) their perceptions of shared decision-making (SDM) during simulated clinical consultations.

    Time frame: Baseline, Up to 1 hour

07

Study locations

1 site
  • University of North Carolina at Chapel Hill, Department of Radiation Oncology
    Chapel Hill, North Carolina 27599, United States
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Dec 2025, 15 months.

Of 1,988 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's 15 months is below that.

Counting every sponsor, half of 2,063 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartActual
Sep 1, 2024
Primary completionActual
Dec 1, 2025
CompletionActual
Dec 1, 2025
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942961
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Sep 1, 2024
Primary completion
Dec 1, 2025
Completion
Dec 1, 2025
Last update
Nov 17, 2026

Study contacts

Daniel R Richardson, MD, MA, MSc
principal investigator · UNC Lineberger Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion